Next-Generation Fibrate Pemafibrate Outperforms Fenofibrate in Fatty Liver Disease Trial

A large randomized controlled trial conducted across 29 centers in Japan has delivered the first head-to-head comparison between pemafibrate, a next-generation selective PPARα modulator, and fenofibrate, the conventional fibrate most widely prescribed for high triglycerides. The results, published in eClinicalMedicine, show that pemafibrate lowered liver injury markers in a dose-dependent fashion, improved measures of liver stiffness, and spared kidney function in patients with metabolic dysfunction-associated steatotic liver disease, or MASLD, complicated by hypertriglyceridemia. For a condition affecting roughly a third of adults worldwide and currently served by only two approved drugs, the findings offer a glimpse of a new therapeutic avenue built on precision targeting of a single nuclear receptor.

MASLD is the liver’s manifestation of metabolic syndrome, a spectrum that begins with simple fat accumulation and can progress to inflammation, known as steatohepatitis, and ultimately to fibrosis and cirrhosis. Lifestyle change remains the foundation of care, and while the thyroid hormone receptor agonist resmetirom and the GLP-1 receptor agonist semaglutide both won U.S. approval in 2024 and 2025 after demonstrating histological benefit, clinicians still lack a broad arsenal. Because dyslipidemia coexists with MASLD in an estimated 26 to 58 percent of cases, drugs that correct blood fats while calming the liver have long attracted interest. Fenofibrate, which activates the nuclear receptor PPARα and drives fatty acid oxidation, has shown hints of benefit in small studies, but its evidence base in fatty liver disease has never been strong enough to establish consensus.

Pemafibrate was engineered to solve a specific pharmacological problem. Rather than broadly activating PPARα the way older fibrates do, it binds selectively and induces ligand-specific conformational changes in the receptor that enhance transcriptional regulation of target genes. Approved in Japan in 2017, the drug had already shown promise in a phase 2 trial where it reduced alanine aminotransferase, or ALT, a sensitive marker of hepatocellular injury, and lowered liver stiffness on magnetic resonance elastography without raising serum creatinine. What remained unknown was whether this molecular refinement translated into clinical superiority over fenofibrate, and whether the drug’s effect scaled with dose. The PRESENT trial was designed to answer both questions simultaneously.

The investigators enrolled 360 participants, all Japanese, with imaging- or biopsy-confirmed fatty liver, triglycerides between 150 and 500 mg/dL, and elevated ALT despite at least three months of diet and exercise efforts. After randomization in equal proportions, 356 patients began treatment: 114 received high-dose pemafibrate at 0.4 mg daily, 117 received low-dose pemafibrate at 0.2 mg daily, and 125 received fenofibrate starting at 53.3 mg daily with cautious escalation permitted. The trial ran for 48 weeks of treatment with a six-week follow-up, and the primary endpoint was the change in ALT at 24 weeks, chosen for its clinical accessibility across the university hospitals and community clinics that participated. Randomization was stratified by diabetes status, triglyceride level, and FIB-4 index to keep the groups balanced, and a prespecified hierarchical testing procedure guarded against false-positive findings.

The results were striking. High-dose pemafibrate cut ALT by an average of 24.0 U/L, a 35.9 percent reduction, while low-dose pemafibrate achieved a 14.8 U/L drop, or 21.8 percent. Fenofibrate managed only a 4.22 U/L decline, essentially 2.1 percent. Both pemafibrate doses beat fenofibrate with high statistical significance under the trial’s fixed-sequence analysis, and, critically, the high dose outperformed the low dose, establishing a genuine dose-response relationship that no previous randomized trial in MASLD had demonstrated. Gamma-glutamyltransferase, another marker of hepatic stress, fell 46.3 percent with high-dose pemafibrate compared with 13.8 percent on fenofibrate, and lipid profiles improved across all three groups without significant differences between them.

The kidney findings may prove just as consequential as the liver data. Fenofibrate is notorious for raising serum creatinine, an effect that can trigger hospitalizations and nephrology referrals in older adults. In this trial, creatinine rose 10.9 percent and estimated glomerular filtration rate fell 9.8 percent in the fenofibrate arm at 24 weeks, whereas pemafibrate produced creatinine increases of just 4.3 percent and 2.1 percent at high and low doses respectively, with correspondingly smaller eGFR declines. The differences were statistically significant at both 24 and 48 weeks. The pharmacological explanation is elegant: fenofibrate is excreted primarily through the urine, while pemafibrate leaves the body mainly via bile. For the many MASLD patients who also carry diabetes, hypertension, or chronic kidney disease, this renal profile could reshape prescribing decisions.

Beyond the blood tests, imaging told a nuanced story. Magnetic resonance elastography, performed under a standardized protocol with central reading, showed liver stiffness falling 9.24 percent in the high-dose pemafibrate group and 8.40 percent in the low-dose group, while stiffness actually rose 3.56 percent on fenofibrate. Vibration-controlled transient elastography, assessed locally without centralized quality control, detected no significant changes in any group, a discrepancy the authors attribute to inter-site variability and MRE’s superior sensitivity for early fibrosis stages. The fibrosis biomarker M2BPGi, which reflects both scarring and inflammatory activity, dropped more than 21 percent with high-dose pemafibrate versus 3.2 percent with fenofibrate, while FIB-4, type IV collagen 7S, and ELF scores remained flat across the board. Liver fat content on MRI-PDFF did not change significantly, consistent with animal work suggesting pemafibrate shrinks individual lipid droplets and accelerates lipid turnover rather than reducing total hepatic triglyceride.

Safety data reinforced the drug’s favorable profile. Treatment-related adverse events numbered 8 in the high-dose pemafibrate arm, 6 in the low-dose arm, and 18 with fenofibrate, with no treatment-related serious events anywhere in the trial. Myalgia was the most common treatment-related complaint, and a single case of rhabdomyolysis in the high-dose pemafibrate group resolved spontaneously after discontinuation. Five hepatobiliary disorder events occurred exclusively in the fenofibrate group, and concomitant statin use, which affects roughly 40 percent of these patients, did not increase adverse events among pemafibrate recipients. Because fibrate-statin combinations carry well-known risks of muscle toxicity through pharmacokinetic interactions, pemafibrate’s minimal impact on statin metabolism adds another practical advantage for a population at elevated cardiovascular risk.

Perhaps the most intriguing finding emerged from the responder analysis. Patients who achieved at least a 30 percent ALT reduction were more likely to have started with higher baseline ALT above the trial median of 56 U/L, and, remarkably, to have lean MASLD defined as a body mass index below 23. Lean patients had nearly four times the odds of responding, an association that persisted in multivariate modeling. The authors suggest that lean MASLD represents a phenotype where hepatic lipid metabolism, rather than systemic metabolic inflammation, dominates the disease process, making a drug that selectively amplifies fatty acid oxidation especially effective. They also point to pemafibrate’s demonstrated suppression of the NLRP3 inflammasome and the NF-κB pathway, which curbs production of tumor necrosis factor-α and interleukin-1β, as a plausible mechanism for the anti-inflammatory signal captured by both ALT and M2BPGi.

The trial’s limitations temper the enthusiasm. There was no liver biopsy, the gold standard for grading steatohepatitis and fibrosis, the design was open-label, lifestyle factors were not standardized, and elastography was available only at some centers. The exclusively Japanese cohort also raises questions about generalizability to other populations. Still, the study’s scale, its stratified randomization, its sensitivity analyses, and its multimodal assessment of inflammation and fibrosis make it the most rigorous test of a selective PPARα modulator in MASLD to date. The authors call for long-term trials with histological endpoints to determine whether pemafibrate can truly modify disease course rather than merely improve surrogates. If those trials succeed, a drug once designed simply to lower triglycerides more cleanly may find its greatest legacy in the liver.

Subject of Research: Efficacy and renal safety of pemafibrate versus fenofibrate in metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia

Article Title: Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trail

Article References: Iwaki, M., Tobita, H., Seko, Y., Kawata, K., Imajo, K., Nagai, K., Kessoku, T., Sakai, E., Nakada, Y., Koyama, S., Kurihashi, T., Yoshioka, W., Yunotani, S., Kohira, T., Takahashi, K., Yamamoto, M., Ishimaru, Y., Oza, N., Yamaguchi, Y., … Takahashi, H. (2026). Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trail. eClinicalMedicine, Article 104226. https://doi.org/10.1016/j.eclinm.2026.104226

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104226

Keywords: pemafibrate, fenofibrate, MASLD, hypertriglyceridemia, PPAR alpha, liver fibrosis, ALT, renal safety, randomized controlled trial, M2BPGi, magnetic resonance elastography, selective PPAR alpha modulator